Ionis Pharmaceuticals Announced Topline, 85-Week Data From The Phase 3 NEURO-TTRansform Study In Hereditary Transthyretin-mediated Amyloid Polyneuropathy Patients, Showing Sustained Improvements In Disease Measures, Favorable Safety & Tolerability Profile
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has announced 85-week data from the Phase 3 NEURO-TTRansform study in hereditary transthyretin-mediated amyloid polyneuropathy patients, showing sustained improvements in disease measures and a favorable safety & tolerability profile.
July 10, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from Ionis Pharmaceuticals' Phase 3 study could potentially boost the company's stock in the short term.
The announcement of positive results from a Phase 3 study is a significant milestone for any pharmaceutical company. This could lead to increased investor confidence in Ionis Pharmaceuticals, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100